Predictions for the Global Life Sciences Industry, 2020

Predictions for the Global Life Sciences Industry, 2020

COVID-19 Pandemic will Drive New Digital-tech Adoption in Drug Discovery and Testing Services, and Federal Funding will Encourage Stronger Product Pipelines

RELEASE DATE
31-Jan-2020
REGION
North America
Research Code: 9AB9-00-C3-00-00
SKU: HC03264-NA-MR_24098

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
HC03264-NA-MR_24098

$1,500.00

$1,125.00 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics.

A common denominator of growth achieved thus far has been developments in the digital arena including, but not limited to, operationalizing Artificial Intelligence platforms, Internet of Medical Things, Real World Evidence, and Blockchain. As use cases and applications in life sciences of the aforementioned technologies increase, its impact will be realized in the coming years. Digital continuity will provide the framework and transparency required throughout the clinical development lifecycle. This study explores specific technologies that are expected to have the largest impact across the drug lifecycle.

While new technologies and platforms are driving the development of novel therapies, the genesis of most therapies has been in academic institutes and research centers. Therefore, economical manufacturing scale-up remains a critical impediment in advancing these therapies from the lab to clinics. Moreover, as pharma companies face pressure from all directions with the risk of negatively- affected profitability, companies are exploring unconventional solutions to introduce optimization and sustainability of profits. One such measure is taking biomanufacturing to next-generation smart facilities that offer greater connectivity, continuity, reproducibility, and efficiency of operations; 2019 witnessed a string of such biopharmaceutical manufacturing facility expansions. This study explores more specific tangents of connected and intelligent bioprocessing and highlights the key companies that are enabling this change.

Multiple approvals and commercial launches clubbed with improvements in manufacturing capability have paved way for next generation and cell and gene therapies to become mainstream. While biopharma investment continues unabated in this segment due to high clinical potential, sustainable reimbursement models will be the key to unlocking true commercial potential. This research service provides insights into the reimbursement models which will change the course of business strategies for pharma companies and associated stakeholders and ensure sustainable growth in the segment.

Lastly, the study highlights the convergence of pharmaceuticals, new diagnostic technologies, and unavoidable need for companion diagnostics, which has been enabled by the regulatory and commercial evolution in the global life sciences industry. With a large number of innovations in diagnostics coming from global IVD players, local companies in the APAC region are using multilateral collaborations to facilitate early introduction of innovations in local markets as well as shaping portfolio choices to bridge gaps in high growth but under-served markets.

Author: Khushbu Jain

Table of Contents

Scope

Key Questions this Study will Answer

Pharma and Biotech

Segment Snapshot—Pharma and Biotech

IVD and Research Tools

Segment Snapshot—IVD and Research Tools

Prediction 1—Artificial Intelligence to Witness Accelerated Adoption in Drug Discovery Innovation in Cancer and Rare Diseases

Key Implications for Stakeholders

Key Companies to Watch in 2020

Prediction 2—Microbiome-based Cancer Therapy to Witness Densest Clinical Pipeline and Capital Influx

Key Implications for Stakeholders

Key Companies to Watch in 2020

Prediction 3—Connected and Intelligent Bioprocessing to Improve Biologic Manufacturing Productivity

Key Implications for Stakeholders

Key Companies to Watch in 2020

Prediction 4—Genome Sequencing Initiatives to Trigger Precision Medicine IVD in Japan

Key Implications for Stakeholders

Key Companies to Watch in 2020

Prediction 5—Annuity-based Model to Catapult Gene Therapy Commercialization in Regulated Markets

Key Implications for Stakeholders

Key Companies to Watch in 2020

Strategic Imperatives for Life Sciences Companies

Impact of Technology on LS Stakeholders

Legal Disclaimer

Geographical Trends

Abbreviations

Abbreviations (continued)

List of Exhibits

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth achieved thus far has been developments in the digital arena including, but not limited to, operationalizing Artificial Intelligence platforms, Internet of Medical Things, Real World Evidence, and Blockchain. As use cases and applications in life sciences of the aforementioned technologies increase, its impact will be realized in the coming years. Digital continuity will provide the framework and transparency required throughout the clinical development lifecycle. This study explores specific technologies that are expected to have the largest impact across the drug lifecycle. While new technologies and platforms are driving the development of novel therapies, the genesis of most therapies has been in academic institutes and research centers. Therefore, economical manufacturing scale-up remains a critical impediment in advancing these therapies from the lab to clinics. Moreover, as pharma companies face pressure from all directions with the risk of negatively- affected profitability, companies are exploring unconventional solutions to introduce optimization and sustainability of profits. One such measure is taking biomanufacturing to next-generation smart facilities that offer greater connectivity, continuity, reproducibility, and efficiency of operations; 2019 witnessed a string of such biopharmaceutical manufacturing facility expansions. This study explores more specific tangents of connected and intelligent bioprocessing and highlights the key companies that are enabling this change. Multiple approvals and commercial launches clubbed with improvements in manufacturing capability have paved way for next generation and cell and gene therapies to become mainstream. While biopharma investment continues unabated in this segment due to high clinical potential, sustainable reimbursement models will be the key to unlocking true commercial potential. This research service provides insights into the reimbursement models which will change the course of business strategies for pharma companies and associated stakeholders and ensure sustainable growth in the segment. Lastly, the study highlights the convergence of pharmaceuticals, new diagnostic technologies, and unavoidable need for companion diagnostics, which has been enabled by the regulatory and commercial evolution in the global life sciences industry. With a large number of innovations in diagnostics coming from global IVD players, local companies in the APAC region are using multilateral collaborations to facilitate early introduction of innovations in local markets as well as shaping portfolio choices to bridge gaps in high growth but under-served markets. Author: Khushbu Jain
More Information
No Index No
Podcast No
Author Khushbu Jain
Industries Healthcare
WIP Number 9AB9-00-C3-00-00
Is Prebook No
GPS Codes 9600-B1,9825-B1,9A06-B1,9562-B1,9571-B1,9573-B1,99BF-B1,99C0-B1,99C1-B1,99C6-B1,99C9-B1,99CB-B1,9837-B1,9568-B1,9611-B1,9627-B1